BioNotebook: PhaseBio closes $40m Series C round led by AstraZeneca, plus five other VC financings

 
• By Mandy Jackson

AstraZeneca led a $40m Series C venture capital round that will fund PhaseBio's Phase IIa clinical trials for drug candidates to treat diabetes and heart failure – two key areas of interest for the UK-based big pharma company.

More from Alimentary/Metabolic

More from Therapy Areas